About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
IMMU - Immunomedics| Previous Close | $85.30 | Open | $85.25 |
| Volume | 3.74M | Market Cap | 19.718B |
| Yield | Last Dividend |
| Gilead Sciences: Debt Fueled Bottom (NAS... | 09/25/20 |
| Gilead Sciences paid a hefty premium for Immunomedics. The breast cancer drug deal is expected to be accretive to EPS by 2023. | |
| The Week Ahead In Biotech: Conference Pr... | 09/20/20 |
| Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccin... | |
| High Hopes for Amgen and Gilead at Europ... | 09/18/20 |
| Europe???s biggest conference for cancer researchers will be a virtual affair this weekend, but it is still expected to be a big deal for companies li... | |
| Immunomedics Announces Encouraging Early... | 09/18/20 |
| Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) | |
| Wachtell regains top M&A perch, leapfrog... | 09/17/20 |
| With the fourth quarter fast approaching, Wachtell, Lipton, Rosen & Katz has passed Latham & Watkins to once again become the top U.S. M&A adviser bas... | |
| Gilead: Markets Like Deal For Immunomedi... | 09/15/20 |
| Gilead is buying Immunomedics for Trodelvy. CEO Daniel O'Day has seen data to be presented at upcoming oncology conference. | |
| Monoclonal Antibodies: A Good Place To B... | 09/15/20 |
| The market is crazy high by most measures. Gilead's intention to buy Immunomedics for $21 billion shows the upside of monoclonal antibodies. | |
| What will it take for Gilead to break ev... | 09/15/20 |
| The deal, which gives Gilead control of Immunomedics, came at a more than 100% premium to the latter firm's most recent stock price. | |
| Futures Power Higher On Upbeat Chinese, ... | 09/15/20 |
| Futures Power Higher On Upbeat Chinese, German Data Tyler Durden Tue, 09/15/2020 - 07:59 US equity futures and world stocks continued their ramp highe... | |
| The Daily Biotech Pulse: Marinus Epileps... | 09/15/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ave... | |
| Merger Arbitrage Mondays - Gilead Scienc... | 09/14/20 |
| Merger activity decreased last week, with two new deals announced. The acquisition of Immunomedics by Gilead Sciences. | |
| SHAREHOLDER ALERT: WeissLaw LLP Investig... | 09/14/20 |
| NEW YORK, Sept. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of... | |
| Stock Market Today: Big Deal! Big Deal! ... | 09/14/20 |
| A roaring day of M&A and other tie-ups helped inject some life into the stock market Monday, as did renewed hopes for a successful vaccine before the ... | |
| What Gilead's $21 Billion Oncology Bet M... | 09/14/20 |
| Gilead makes a major oncology play, spending $21 billion on Immunomedics. When will the deal be accretive, and what does this mean? Gilead seems like ... | |
| IMMUNOMEDICS INVESTOR ALERT by the Forme... | 09/14/20 |
| NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (???KSF???) a... | |
| Gilead Sciences And Immunomedics: Buy Po... | 09/14/20 |
| Gilead Sciences has announced it's buying Immunomedics for $21 billion - we don't expect the market to react favorably. | |
| Gilead Analysts Dissect Immunomedics Dea... | 09/14/20 |
| Gilead Sciences, Inc. (NASDAQ: GILD ) announced over the weekend a deal to buy Immunomedics, Inc. Latest Ratings for ??? Full story available on Benzi... | |
| Stocks making the biggest moves midday: ... | 09/14/20 |
| Oracle, Nvidia and Immunomedics were all up on dealmaking news. Overstock got a boost after an analyst upgrade. | |
| Why Sutro Biopharma's Stock Is Trading H... | 09/14/20 |
| Sutro Biopharma (NASDAQ: STRO ) shares are trading higher on Monday after peer company Immunomedics , who also works to treat cancer, was acquired by ... | |
| Gilead Bolsters Cancer Portfolio With $2... | 09/14/20 |
| Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access ... | |
| Are Immunomedics Shareholders Getting En... | 09/14/20 |
| No summary available. | |
| Dow climbs 230 points as tech giants ral... | 09/14/20 |
| Summary List Placement US stocks climbed on Monday as new deals and shifting investor sentiments boosted tech giants. Oracle leaped following reports ... | |
| Thinking about trading options or stock ... | 09/14/20 |
| NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMU, ORCL, VIR, UAL, and TSLA. Click a link below th... | |
| NVDA, ORCL among premarket gainers | 09/14/20 |
| Immunomedics (IMMU +106% after Gilead to buy the company for $21B (~$88/share). Cassava Sciences (SAVA +94% on positive data on lead drug in Alzheimer... | |
| Inside Grand Rounds' $175 million fundin... | 09/14/20 |
| Summary List Placement Hello, Happy Monday! Over the weekend, AstraZeneca and Oxford resumed their coronavirus vaccine trial and Gilead Sciences struc... | |
| Stocks making the biggest moves premarke... | 09/14/20 |
| Nvidia, Oracle and Immunomedics all surged on dealmaking activity. Delta backs new debt with its frequent flyer program. | |
| Hold rating | 09/15/20 |
| Jefferies downgrades from Buy to Hold rating and raises Price Target from $55.00 to $88.00 | |
| Hold rating | 09/14/20 |
| HC Wainwright & Co. downgrades from Buy to Neutral rating and raises Price Target from $56.00 to $88.00 | |
| Hold rating | 08/10/20 |
| Morgan Stanley maintains Equal-Weight rating and raises Price Target from $32.00 to $40.00 | |
| Strong Buy rating | 08/06/20 |
| Piper Sandler maintains Overweight rating and raises Price Target from $55.00 to $60.00 | |
| Buy rating | 08/03/20 |
| B of A Securities maintains Buy rating and raises Price Target from $45.00 to $47.00 | |
| Buy rating | 07/27/20 |
| Jefferies maintains Buy rating and raises Price Target from $41.00 to $55.00 | |
| Buy rating | 07/07/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $54.00 to $56.00 | |
| Date | 2020-08-05 (AMC) | Est. (EPS/Rev.) | ($0.35)/ 12.91M |
| Actual (EPS/Rev.) | $-0.73/ $20.07 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Portfolio | TraderCZ | 99.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| AungPan Thar's Swing trading | Kyaw Aung | 65.00 % | Subscribe |
| smashingdon | Paul | 63.00 % | Follow |
| Hi America | Lawrence | 62.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
